AbbVie (ABBV) call put ratio 1.8 calls to 1 put into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Abbvie (ABBV) PT Raised to $212 at Goldman Sachs
February 3, 2025 5:17 AM ESTGoldman Sachs analyst Chris Shibutani raised the price target on Abbvie (NYSE: ABBV) to $212.00 (from $208.00) while maintaining a Buy rating.
The analyst comments "Relative outperformance from ABBV shares (+4.7% on Friday vs. XLV -0.3%) was earned in our view, with continued strong momentum from Skyrizi and Rinvoq enabling the delivery of... More
